

Patient - PACT

New Clinical Trial and Research



Trial title	PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial
Trial synopsis	<p>Low blood oxygen during exercise is common in people with pulmonary fibrosis. This is sometimes treated with ambulatory oxygen therapy, which involves breathing oxygen during physical activity. It is not known whether ambulatory oxygen therapy helps people with pulmonary fibrosis to be more active, with fewer symptoms. Recently portable oxygen concentrators have become available, which are lighter and easier to use than the traditional method of delivering treatment with cylinder oxygen. This could increase the benefits of treatment.</p> <p>This trial will test whether ambulatory oxygen, delivered using a portable concentrator, can improve physical activity and symptoms in people with pulmonary fibrosis. Participants will be randomly allocated to receive oxygen or air (delivered using identical portable concentrators) for 6 months. We will measure physical activity levels, exercise capacity, symptoms and quality of life at the beginning of the trial, 3 months later and 6 months later. The results of this trial will provide patients and health professionals with certainty regarding the impact of ambulatory oxygen therapy in people with pulmonary fibrosis.</p>
Investigational medicinal product, comparator and randomisation	Portable oxygen concentrator (Inogen One G3 HF)
Disease target	Fibrotic interstitial lung disease
Sponsor	Monash University
Duration	6 months
Trial Status	Recruiting
Lead site(s) in Australia	Alfred Health (Vic)
Lead site(s) in New Zealand	N/A
Additional sites	Austin Health (Vic) Royal Prince Alfred Hospital (NSW) The Prince Charles Hospital (Qld) The Royal Melbourne Hospital (VIC)
Contact	pactcoordinator@cre-pf.org.au